Announcement • Jun 16
Outlook Therapeutics, Inc. Announces FDA Acceptance Of Resubmitted Biologics License Application For ONS-5010/LYTENAVA (Bevacizumab-Vikg) As A Treatment For Wet AMD Outlook Therapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA for the treatment of neovascular age-related macular degeneration (nAMD), or wet AMD. The Company has been informed that the resubmission is a Class 1 review, with a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2026. When approved, ONS-5010/LYTENAVA will be the first and only FDA-approved ophthalmic formulation of bevacizumab supported by standardized manufacturing, FDA-approved labeling, and robust pharmacovigilance. Outlook Therapeutics has initiated pre-launch activities in anticipation of the pending BLA approval. ONS-5010/LYTENAVA is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. LYTENAVA (bevacizumab gamma) is the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD. In certain European Union Member States, ONS-5010/LYTENAVA must receive pricing and reimbursement approval before it can be sold. In the United States, ONS-5010/LYTENAVA (bevacizumab-vikg) is investigational. When approved, it will be the first ophthalmic formulation approved by the FDA. Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina. OTLK
Live News • Jun 14
Outlook Therapeutics Receives FDA Fast-Track for Lytenava With Key Decision Expected in 60 Days Outlook Therapeutics’ resubmitted Biologics License Application for ONS-5010/Lytenava for wet age-related macular degeneration has been accepted by the FDA and assigned a fast-track Class 1 review.
The FDA has indicated that existing data provide substantial evidence of effectiveness, so no new clinical trials are required, and labeling discussions are underway.
A PDUFA decision is expected roughly 60 days after the June 1, 2026 resubmission. Lytenava is already in commercial rollout in parts of Europe and the UK through new distribution agreements and planned market expansion.
The combination of an accepted, expedited FDA review and early commercial activity in Europe and the UK puts regulatory timing and early market execution in clear focus for this company.
Investors may want to pay close attention to the upcoming PDUFA date and any updates on U.S. labeling, as well as developments in how European and UK distribution agreements translate into real-world uptake and revenue risk or opportunity. Major Estimate Revision • Jun 12
Consensus revenue estimates increase by 200% The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$400.0k to US$1.20m. EPS estimate unchanged from -US$0.53 at last update. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target up from US$4.17 to US$5.50. Share price rose 57% to US$1.22 over the past week. 
